Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANGPT4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length) | ANGPT4 Full-Length Recombinant Protein / Domain Variants. High purity (>95%), Endotoxin <1 EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). | View ANGPT4 Products |
| Antigen (ECD-Fc) | ANGPT4 ECD-Fc / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View ANGPT4 Products |
| Gene Delivery | ANGPT4 Promise-ORF / Lentivirus. Full-length ORF for stable secreting cell lines. | View ANGPT4 Products |
| Benchmark Ab | Anti-ANGPT4 Neutralizing Antibody / Biosimilar. Recombinant positive control for binding and blockade assays. | View ANGPT4 Products |
| Validator | ANGPT4 siRNA Set. For knockdown verification and pathway analysis. | View ANGPT4 Products |
| Related Target A | TEK (TIE2). Primary receptor for the Angiopoietin family. | View TEK Products |
| Related Target B | ANGPT2. Crucial for subfamily cross-reactivity screening. | View ANGPT2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Toxicity | Strictly sequence-verified homolog panels (ANGPT1/2/3/4) available for precise selectivity counter-screening. |
| Native Glycosylation & Folding | HEK293 Expressed (Native Glycosylation) to ensure proper oligomerization necessary for TEK receptor engagement. |
| Lack of Reliable Controls | Sequence-verified recombinant positive control antibodies included. |
| False Positives in Cell Assays | Endotoxin Controlled (<1 EU/ug) proteins and validated siRNAs ensure true biological signaling responses. |
Live ANGPT4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ANGPT4 therapeutics is evolving within the broader Angiopoietin/TIE2 axis. While historically overshadowed by ANGPT2, major players are increasingly recognizing ANGPT4's unique role in regulating vascular permeability and angiogenesis under specific pathological conditions such as hypoxia. As first-generation anti-angiogenic therapies (like VEGF inhibitors) encounter resistance in the clinic, the next wave of R&D is targeting alternative angiogenic pathways. Combinatorial approaches targeting both VEGF and ANGPT4, or bispecific modalities spanning multiple Angiopoietins, represent a critical frontier in tackling refractory solid tumors and complex retinal neovascular diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Early-stage Biotech | Ophthalmology (AMD) | Receptor Blocking Assay (Need HEK293 expressed, active ANGPT4) |
| Bispecific Antibodies | Global Pharma | Solid Tumors (VEGF-resistant) | Cross-reactivity Panel (Need high-purity ANGPT homolog proteins) |
| Recombinant Proteins | Regenerative Medicine Focus | Ischemic Diseases | Cell Survival Assays (Need Endotoxin Controlled, <1EU/ug proteins) |
ANGPT4 Key Molecular Features
According to UniProt entry Q9Y264, ANGPT4 contains a Fibrinogen C-terminal domain (evidence: UniProt domain). This domain is critical for receptor binding and oligomerization. Additionally, a naturally occurring variant dbSNP rs869171 (VAR_049070 in UniProt) has been documented, which may influence protein function or disease association. These features are essential considerations when designing assays and therapeutics targeting ANGPT4, particularly for selectivity against homologous family members.